Humanized mice, a new model to study the influence of drug treatment on neonatal sepsis

Infection and Immunity

Volumn 81, Issue 5, 2013, Pages 1520-1531

  Ernst, Wolfgang ^a   Zimara, Nicole ^a   Hanses, Frank ^a   Männel, Daniela N ^a   Seelbach Göbel, Birgit ^a   Wege, Anja K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CD33 ANTIGEN; CD45 ANTIGEN; GAMMA INTERFERON; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR;

AGRICULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BONE MARROW CELL; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; FETUS; GROUP B STREPTOCOCCAL INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO STUDY; LEUKOCYTE MIGRATION; MOUSE; NEWBORN SEPSIS; NONHUMAN; PERINATAL CARE; PHENOTYPE; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BACTERIAL LOAD; BETAMETHASONE; BONE MARROW; BONE MARROW CELLS; CELL MOVEMENT; COLONY COUNT, MICROBIAL; CYTOKINES; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; INDOMETHACIN; LEUKOCYTES; MICE; SEPSIS; SPLEEN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 84877152452     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01235-12     Document Type: Article

References (66)

1. Maisey HC, Doran KS, Nizet V. 2009. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert Rev. Mol. Med. 10:e27. doi:10.1017/S1462399408000811.
2. Koenig JM, Keenan WJ. 2009. Group B streptococcus and early-onset sepsis in the era of maternal prophylaxis. Pediatr. Clin. North Am. 56: 689-708.
3. Henneke P, Berner R. 2006. Interaction of neonatal phagocytes with group B streptococcus: recognition and response. Infect. Immun. 74: 3085-3095.
4. Shet A, Ferrieri P. 2004. Neonatal & maternal group B streptococcal infections: a comprehensive review. Indian J. Med. Res. 120:141-150.
5. Rajagopal L. 2009. Understanding the regulation of group B streptococcal virulence factors. Future Microbiol. 4:201-221.
6. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M. 2005. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106:1565-1573.
7. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, Greiner DL, Handgretinger R. 2005. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174:6477-6489.
8. Mota J, Rico-Hesse R. 2009. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J. Virol. 83:8638-8645.
9. Joseph A, Zheng JH, Chen K, Dutta M, Chen C, Stiegler G, Kunert R, Follenzi A, Goldstein H. 2010. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J. Virol. 84:6645-6653.
10. Wege AK, Florian C, Ernst W, Zimara N, Schleicher U, Hanses F, Schmid M, Ritter U. 2012. Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response. PLoS Negl. Trop. Dis. 6:e1741. doi:10.1371/journal .pntd.0001741.
11. Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, Männel DN, Ortmann O, Kroemer A, Brockhoff G. 2011. Humanized tumor mice-a new model to study and manipulate the immune response in advanced cancer therapy. Int. J. Cancer 129:2194-2206.
12. Chirico G. 2005. Development of the immune system in neonates. J. Arab Neonatol. Forum 2(2):5-11.
13. Wolach B, Sonnenschein D, Gavrieli R, Chomsky O, Pomeranz A, Yuli I. 1998. Neonatal neutrophil inflammatory responses: parallel studies of light scattering, cell polarization, chemotaxis, superoxide release, and bactericidal ctivity. Am. J. Hematol. 58:8-15.
14. Gille C, Orlikowsky TW, Spring B, Hartwig UF, Wilhelm A, Wirth A, Goecke B, Handgretinger R, Poets CF, André MC. 2012. Monocytes derived from humanized neonatal NOD/SCID/IL2R-null mice are phenotypically immature and exhibit functional impairments. Hum. Immunol. 73:346-354.
15. Yamada A, Kaneyuki T, Hara A, Rothstein DM, Yokoyama MM. 1992. CD45 isoform expression on human neonatal T cells: expression and turnover of CD45 isoforms on neonatal versus adult T cells after activation. Cell. Immunol. 142:114-124.
16. Schelonka RL, Infante AJ. 1998. Neonatal immunology. Semin. Perinatol. 22:2-14.
17. Marodi L. 2002. Down-regulation of Th1 responses in human neonates. Clin. Exp. Immunol. 128:1-2.
18. Adkins B, Leclerc C, Marshall-Clarke S. 2004. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4:553-564.
19. McDermott SP, Eppert K, Lechman ER, Doedens M, Dick JE. 2010. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 116:193-200.
20. Marshall-Clarke S, Reen D, Tasker L, Hassan J. 2000. Neonatal immunity: how well has it grown up. Immunol. Today 21:35-41.
21. Jones CA, Holloway JA, Warner JO. 2002. Phenotype of fetal monocytes and B lymphocytes during the third trimester of pregnancy. J. Reprod. Immunol. 56:45-60.
22. Splawski JB, Jelinek DF, Lipsky PE. 1991. Delineation of the functional capacity of human neonatal lymphocytes. J. Clin. Invest. 87:545-553.
23. Recher M, Berglund LJ, Avery DT, Cowan MJ, Gennery AR, Smart J, Peake J, Wong M, Pai SY, Baxi S, Walter JE, Palendira U, Tangye GA, Rice M, Brothers S, Al-Herz W, Oettgen H, Eibel H, Puck JM, Cattaneo F, Ziegler JB, Giliani S, Tangye SG, Notarangelo LD. 2011. IL-21 is the primary common - chain-binding cytokine required for human B-cell differentiation in vivo. Blood 118:6824-6835.
24. Zola H, Fusco M, Macardle PJ, Flego L, Roberton D. 1995. Expression of cytokine receptors by human cord blood lymphocytes: comparison with adult blood lymphocytes. Pediatr. Res. 38:397-403.
25. Saito S, Morii T, Umekage H, Makita K, Nishikawa K, Narita N, Ichijo M, Morikawa H, Ishii N, Nakamura M, Sugamura K. 1996. Expression of the interleukin-2 receptor gamma chain on cord blood mononuclear cells. Blood 87:3344-3350.
26. Zilow G, Zilow EP, Burger R, Linderkamp O. 1993. Complement activation in newborn infants with early onset infection. Pediatr. Res. 34:199-203.
27. Sonntag J, Brandenburg U, Polzehl D, Strauss E, Vogel M, Dudenhausen JW, Obladen M. 1998. Complement system in healthy term newborns: reference values in umbilical cord blood. Pediatr. Dev. Pathol. 1:131-135.
28. Drew JH, Arroyave CM. 1980. The complement system of the newborn infant. Biol. Neonate 37:209-217.
29. Lassiter HA, Watson SW, Seifring ML, Tanner JE. 1992. Complement factor 9 deficiency in serum of human neonates. J. Infect. Dis. 166:53-57.
30. Harvey BS, Baker CJ, Edwards MS. 1992. Contributions of complement and immunoglobulin to neutrophil-mediated killing of enterococci. Infect. Immun. 60:3635-3640.
31. Foreman O, Kavirayani AM, Griffey SM, Reader R, Shultz LD. 2011. Opportunistic bacterial infections in breeding colonies of the NSG mouse strain. Vet. Pathol. 48:495-499.
32. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL. 1995. Multiple defects in innate and adaptive immunologic function in NOD/ LtSz-scid mice. J. Immunol. 154:180-191.
33. Goldenberg RL. 2002. The management of preterm labor. Obstet. Gynecol. 100:1020-1037.
34. Suarez RD, Grobman WA, Parilla D. 2001. Indomethacin tocolysis and intraventricular hemorrhage. Obstet. Gynecol. 97:921-925.
35. Locksmith G, Duff P. 2001. Infection, antibiotics, and preterm delivery. Semin. Perinatol. 25:295-309.
36. Agrawal V, Hirsch E. 2012. Intrauterine infection and preterm labor. Semin. Fetal Neonatal Med. 17:12-19.
37. Gibson RL, Truog WE, Henderson WR, Jr, Redding GJ. 1992. Group B streptococcal sepsis in piglets: effect of combined pentoxifylline and indomethacin pretreatment. Pediatr. Res. 31:222-227.
38. Pauly TH, Aziz SM, Horstman SJ, Gillespie MN. 1992. Impact of prostaglandin and thromboxane synthesis blockade on disposition of group B streptococcus in lung and liver of intact piglet. Pediatr. Res. 31: 14-17.
39. Tran TV, Weisman LE. 2004. Dexamethasone effects on group B streptococcal infection in newborn rats. Pediatr. Infect. Dis. J. 23:47-52.
40. Short BL, Miller MK, Pan J. 1988. Group B streptococcal (GBSS) newborn septic shock model: the role of prostaglandins. Prog. Clin. Biol. Res. 264:333-336.
41. Mestas J, Hughes CC. 2004. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172:2731-2738.
42. Bryant CE, Monie TP. 2012. Mice, men and the relatives: cross-species studies underpin innate immunity. Open Biol. 2:120015. doi:10.1098/rsob .120015.
43. Kronforst KD, Mancuso CJ, Pettengill M, Ninkovic J, Power Coombs MR, Stevens C, Otto M, Mallard C, Wang X, Goldmann D, Levy O. 2012. A neonatal model of intravenous Staphylococcus epidermidis infection in mice 24 h old enables characterization of early innate immune responses. PLoS One 7:e43897. doi:10.1371/journal.pone.0043897.
44. Mittal R, Gonzalez-Gomez I, Panigrahy A, Goth K, Bonnet R, Prasadarao NV. 2010. IL-10 administration reduces PGE-2 levels and promotes CR3-mediated clearance of Escherichia coli K1 by phagocytes in meningitis. J. Exp. Med. 207:1307-1319.
45. Placencia FX, Kong L, Weisman LE. 2009. Treatment of methicillinresistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin. Pediatr. Res. 65:420-424.
46. Wynn JL, Scumpia PO, Winfield RD, Delano MJ, Kelly-Scumpia K, Barker T, Ungaro R, Levy O, Moldawer LL. 2008. Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists. Blood 112:1750-1758.
47. Henneke P, Dramsi S, Mancuso G, Chraibi K, Pellegrini E, Theilacker C, Hübner J, Santos-Sierra S, Teti G, Golenbock DT, Poyart C, Trieu- Cuot P. 2008. Lipoproteins are critical TLR2 activating toxins in group B streptococcal sepsis. J. Immunol. 180:6149-6158.
48. Kenzel S, Mancuso G, Malley R, Teti G, Golenbock DT, Henneke P. 2006. c-Jun kinase is a critical signaling molecule in a neonatal model of group B streptococcal sepsis. J. Immunol. 176:3181-3188.
49. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. 1994. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann. Intern. Med. 120:771-783.
50. Zeni F, Freeman B, Natanson C. 1997. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med. 25:1095-1100.
51. Sauter C, Wolfensberger C. 1980. Interferon in human serum after injection of endotoxin. Lancet ii:852-853.
52. Warren HS. 2009. Editorial: mouse models to study sepsis syndrome in humans. J. Leukoc. Biol. 86:199-201.
53. Ren Y, Xie Y, Jiang G, Fan J, Yeung J, Li W, Tam PK, Savill J. 2008. Apoptotic cells protect mice against lipopolysaccharide-induced shock. J. Immunol. 180:4978-4985.
54. Asher A, Mulé JJ, Reichert CM, Shiloni E, Rosenberg SA. 1987. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol. 138:963-974.
55. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, et al. 1987. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J. Clin. Oncol. 5:1942-1951.
56. Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, Hanke T, Hünig T, Kerkau T, Gold R. 2005. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 202:445-455.
57. Hunig T, Dennehy K. 2005. CD28 superagonists: mode of action and therapeutic potential. Immunol. Lett. 100:21-28.
58. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355: 1018-1028.
59. Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS. 2009. Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J. Leukoc. Biol. 86:219-227.
60. Mancuso G, Tomasello F, Migliardo M, Delfino D, Cochran J, Cook JA, Teti G. 1994. Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infect. Immun. 62:4997-5002.
61. Cusumano V, Mancuso G, Genovese F, Delfino D, Beninati C, Losi E, Teti G. 1996. Role of gamma interferon in a neonatal mouse model of group B streptococcal disease. Infect. Immun. 64:2941-2944.
62. Mancuso G, Cusumano V, Genovese F, Gambuzza M, Beninati C, Teti G. 1997. Role of interleukin 12 in experimental neonatal sepsis caused by group B streptococci. Infect. Immun. 65:3731-3735.
63. Wynn JL, Scumpia PO, Delano MJ, O'Malley KA, Ungaro R, Abouhamze A, Moldawer KL. 2007. Increased mortality and altered immunity in neonatal sepsis produced by generalized peritonitis. Shock 28: 675-683.
64. Kurt AN, Aygun AD, Godekmerdan A, Kurt A, Dogan Y, Yilmaz E. 2007. Serum IL-1beta, IL-6, IL-8, and TNF-alpha levels in early diagnosis and management of neonatal sepsis. Mediators Inflamm. 2007:31397.
65. Lvovschi V, Arnaud L, Parizot C, Freund Y, Juillien G, Ghillani-Dalbin P, Bouberima M, Larsen M, Riou B, Gorochov G, Hausfater P. 2011. Cytokine profiles in sepsis have limited relevance for stratifying patients in the emergency department: a prospective observational study. PLoS One 6:e28870. doi:10.1371/journal.pone.0028870.
66. Runkle B, Goldberg RN, Streitfeld MM, Clark MR, Buron E, Setzer ES, Bancalari E. 1984. Cardiovascular changes in group B streptococcal sepsis in the piglet: response to indomethacin and relationship to prostacyclin and thromboxane A2. Pediatr. Res. 18:874-878.